Souhaitez-vous accéder aux communiqués récents ?

Gelatin trick 2026 warning: does the viral gelatin trick recipe work? Pink gelatin trick, ice gelatin trick, and Gelatine Sculpt examined.

2026 SteelPower performance report covers male enhancement formula details, ingredient research context, pricing, and guarantee disclosures.

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...

Gelatide Drops under investigation: 2026 consumer report on Gelatide-1 claims, fake gelatin trick recipe, ingredient research, and refund terms.

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials

TORONTO, March 28, 2026 (GLOBE NEWSWIRE) -- (TSX: SPFD) Mulvihill Enhanced Split Preferred Share ETF (the “Fund”) (formerly Mulvihill U.S. Health Care Enhanced Yield ETF) announces results of...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...